+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Guanylate Cyclase"

Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2024 - Product Thumbnail Image

Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Guanylate Cyclase-Coupled Receptor Activators - Pipeline Insight, 2024 - Product Thumbnail Image

Guanylate Cyclase-Coupled Receptor Activators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
MK5475 Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

MK5475 Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase (Cyclizing) or GC or EC 4.6.1.2) - Drugs in Development, 2021 - Product Thumbnail Image

Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase (Cyclizing) or GC or EC 4.6.1.2) - Drugs in Development, 2021

  • Report
  • April 2021
  • 30 Pages
  • Global
From
Soluble Guanylate Cyclase - Pipeline Review, H2 2020 - Product Thumbnail Image

Soluble Guanylate Cyclase - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 108 Pages
  • Global
From
Soluble Guanylate Cyclase Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Soluble Guanylate Cyclase Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 79 Pages
  • Global
From
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 113 Pages
  • Global
From
Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase or GC or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase or GC or EC 4.6.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 71 Pages
  • Global
From
Atrial Natriuretic Peptide Receptor 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Atrial Natriuretic Peptide Receptor 1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 44 Pages
  • Global
From
Atrial Natriuretic Peptide Receptor 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Atrial Natriuretic Peptide Receptor 2 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 39 Pages
  • Global
From
Contemporary Accounts in Drug Discovery and Development. Edition No. 1 - Product Thumbnail Image

Contemporary Accounts in Drug Discovery and Development. Edition No. 1

  • Book
  • April 2022
  • 480 Pages
Successful Drug Discovery, Volume 4. Edition No. 1 - Product Thumbnail Image

Successful Drug Discovery, Volume 4. Edition No. 1

  • Book
  • September 2019
  • 272 Pages
  • 12 Results (Page 1 of 1)
Loading Indicator

The Guanylate Cyclase market is a subset of the Drug Discovery market, which focuses on the development of new drugs and treatments for various diseases. Guanylate Cyclase is an enzyme that plays a role in the regulation of blood pressure, and is a target for drug discovery. Companies in this market are researching and developing new drugs that target this enzyme, in order to treat diseases such as hypertension, pulmonary arterial hypertension, and heart failure. The Guanylate Cyclase market is highly competitive, with many companies investing in research and development to create new drugs and treatments. Companies in this market are also investing in clinical trials to test the efficacy of their drugs. Some companies in the Guanylate Cyclase market include Novartis, Pfizer, Merck, AstraZeneca, and GlaxoSmithKline. Show Less Read more